Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia

INCLUSION CRITERIA: * Written informed consent has been obtained; * ≥18 years of age; * Suspected MRSA bacteremia determined by clinical judgment or 2 sets of positive blood cultures; * Increased risk for an MRSA infection EXCLUSION CRITERIA: * Received \>48 hours of vancomycin therapy in the 7 days prior to enrollment; * Received any systemic antibacterial agents potentially effective against MRSA in the 7 days prior to enrollment; * Anticipated requirement of antibiotics potentially effective against MRSA; * High likelihood of left-sided infective endocarditis (LIE); * Known/suspected polymicrobial bacteremia or infection including Gram-negative infections; * Known pneumonia, osteomyelitis, or meningitis; * Intravascular foreign material unless material intended removed within 3 days; * Prosthetic heart valve; * Cardiac decompensation, valve damage, or both such that high likelihood of valve replacement surgery within first 3 days of study drug treatment; * Moribund clinical condition such that death likely within first 3 days of study drug treatment; * Shock or hypotension or oliguria unresponsive to fluids after 4 hours; * Received investigational drug within 30 days of study entry * Received statins or other therapy with associated with rhabdomyolysis within 2 days of study entry; * History of significant allergy or intolerance to vancomycin or daptomycin * Infecting pathogen with confirmed reduced susceptibility to vancomycin; * Infecting pathogen with confirmed redu…